Citations (120)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Daniel Auclair, Carol Mansfield, Mark A Fiala, Ajai Chari, Craig E Cole, Jonathan L Kaufman, Gregory J Orloff, David S Siegel, Jeffrey A Zonder, Brennan Mange, Jennifer Yesil, Mehul Dalal & Joseph R Mikhael. (2022) Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. Patient Preference and Adherence 16, pages 573-585.
Read now
Read now
Cristina Villanueva-Bueno, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Álvaro Giménez-Manzorro, Almudena Ribed, Belén Marzal-Alfaro, José Luis Revuelta-Herrero, Eva Gonzalez-Haba, Ana Herranz & Maria Sanjurjo. (2022) Medication guide for the perioperative management of oral antineoplastic agents in cancer patients. Expert Opinion on Drug Safety 21:1, pages 107-119.
Read now
Read now
Hannah Le, Kellie Ryan, Svea K Wahlstrom, Martine C Maculaitis, Oliver Will, Emily Mulvihill & Thomas W LeBlanc. (2021) Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects. Patient Preference and Adherence 15, pages 99-110.
Read now
Read now
Daniela Geba, Johan Mohd Sani, Michaela Gascon, Rebecca Hahn, Kavita Aggarwal & Jinky Rosselli. (2021) Hereditary angioedema patients would prefer newer-generation oral prophylaxis. Journal of Drug Assessment 10:1, pages 51-56.
Read now
Read now
Badriyah Shadid Alotaibi, Manal Buabeid, Nihal Abdalla Ibrahim, Zelal Jaber Kharaba, Munazza Ijaz & Ghulam Murtaza. (2021) Recent strategies driving oral biologic administration. Expert Review of Vaccines 20:12, pages 1587-1601.
Read now
Read now
Wendy Y. Cheng, Ambika Satija, Hoi Ching Cheung, Kala Hill, Tim Wert, François Laliberté & Patrick Lefebvre. (2021) Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes. Hematology 26:1, pages 261-270.
Read now
Read now
Edgardo S Santos & Lowell Hart. (2020) Advanced Squamous Cell Carcinoma of the Lung: Current Treatment Approaches and the Role of Afatinib. OncoTargets and Therapy 13, pages 9305-9321.
Read now
Read now
Tetsuhiro Chiba, Atsushi Hiraoka, Shigeru Mikami, Masami Shinozaki, Yukio Osaki, Masamichi Obu, Takamasa Ohki, Naoyuki Mita, Dianne Ledesma, Nariaki Yoshihara, Kathleen Beusterien, Kaitlan Amos, John FP Bridges & Osamu Yokosuka. (2019) Japanese patient preferences regarding intermediate to advanced hepatocellular carcinoma treatments. Patient Preference and Adherence 13, pages 637-647.
Read now
Read now
Petri Mankinen, Ville Vihervaara, Saku Torvinen, Janne Martikainen & Erkki Soini. (2019) Costs of administration, travelling, and productivity losses associated with hospital administration of multiple myeloma drugs in Finland. Journal of Medical Economics 22:4, pages 328-335.
Read now
Read now
Driton Vllasaliu, Maya Thanou, Snjezana Stolnik & Robyn Fowler. (2018) Recent advances in oral delivery of biologics: nanomedicine and physical modes of delivery. Expert Opinion on Drug Delivery 15:8, pages 759-770.
Read now
Read now
Julieta González, Matías Quiroga, Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Ana Herranz-Alonso & María Sanjurjo Sáez. (2018) Posology adjustments of oral antineoplastic agents for special populations: patients with renal impairment, hepatic impairment and hematologic toxicities. Expert Opinion on Drug Safety 17:6, pages 553-572.
Read now
Read now
Articles from other publishers (109)
Hua Liu, Yanmiao Fan, Jie Zhong, Michael Malkoch, Zhengwei Cai & Zhengting Wang. (2023) Advance in oral delivery of living material. Biomedical Technology 3, pages 26-39.
Crossref
Crossref
Pauline Lory, Louise Perche, Julie Blanc, Bastian Fouquier, Audrey Giroux, Amélie Thomassin, Madeline Devaux, Amélie Renaudin, Cyril Di Martino, Valérie Quipourt, Leïla Bengrine-Lefèvre & Antonin Schmitt. (2022) Adherence to oral anti-cancer therapies in older patients is similar to that of younger patients. Journal of Oncology Pharmacy Practice 29:5, pages 1154-1162.
Crossref
Crossref
Mayumi Komine, Hyunchung Kim, Jingbo Yi, Yichen Zhong, Yoko Sakai, Bruce Crawford, Katsuyoshi Habiro, Yusuke Hikichi & Steven R. Feldman. (2023) A discrete choice experiment on oral and injection treatment preferences among moderate‐to‐severe psoriasis patients in Japan. The Journal of Dermatology 50:6, pages 766-777.
Crossref
Crossref
Federica Lacarbonara, Marco Di Nitto, Valentina Biagioli, Angela Durante, Fabio Sollazzo, Francesco Torino, Mario Roselli, Rosaria Alvaro & Ercole Vellone. (2023) Development and Content Validity of the Self-Care of Oral Anticancer Agents Index (SCOAAI). Seminars in Oncology Nursing 39:3, pages 151402.
Crossref
Crossref
Audrey Delmas, Laurie Batchelder, Ira Arora, Solene Bayet, David Bruhn, Alice Eberhardt, Stephanie Philpott & Ana Maria Rodriguez-Leboeuf. (2023) Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia. Frontiers in Oncology 13.
Crossref
Crossref
Solene Masloh, Maxime Culot, Fabien Gosselet, Anne Chevrel, Leonardo Scapozza & Magali Zeisser Labouebe. (2023) Challenges and Opportunities in the Oral Delivery of Recombinant Biologics. Pharmaceutics 15:5, pages 1415.
Crossref
Crossref
Alexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, Jessica C. Hassel, Imke Grimmelmann, Ralf Gutzmer, Max Schlaak, Markus V. Heppt, Pia Dücker, Svea Hüning, Lena Schulmeyer, Bastian Schilling, Sebastian Haferkamp, Mirjana Ziemer, Rose K. C. Moritz, Victoria Hagelstein, Patrick Terheyden, Christian Posch, Maria R. Gaiser, Peter Kropp, Steffen Emmert, Britta Müller & Julia K. Tietze. (2022) Immune checkpoint inhibition and targeted therapy for melanoma: A patient‐oriented cross‐sectional comparative multicentre study. Journal of the European Academy of Dermatology and Venereology 37:5, pages 884-893.
Crossref
Crossref
Tsvetelina H. Baryakova, Brett H. Pogostin, Robert Langer & Kevin J. McHugh. (2023) Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Nature Reviews Drug Discovery 22:5, pages 387-409.
Crossref
Crossref
Laure Kornreich, Daniel Orbach, Nayla Nicolas, Hervé J Brisse, Pablo Berlanga, Anne-Sophie Defachelles, Ludovic Mansuy, Cécile Verite, Laure Saumet, Marie Karanian & Nadège Corradini. (2023) Oral vinorelbine in young patients with desmoid-type fibromatosis. Tumori Journal, pages 030089162311698.
Crossref
Crossref
Eward J Melis, Jeannette EF Zwart-van Rijkom, Toine CG Egberts, Bart JF van den Bemt, Petronella O Witteveen & Helga Gardarsdottir. (2022) The association between patient satisfaction with information and adherence to oral anticancer agents. Journal of Oncology Pharmacy Practice 29:3, pages 637-645.
Crossref
Crossref
Neehar D. Parikh, Allicia Girvan, Joshua Coulter, Jonathon Gable, Jiat Ling Poon, Sangmi Kim, Anindya Chatterjee & Marco Boeri. (2023) Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study. BMC Cancer 23:1.
Crossref
Crossref
Hope S. Rugo, Gerardo A. Umanzor, Francisco J. Barrios, Rosa H. Vasallo, Marco A. Chivalan, Suyapa Bejarano, Julio R. Ramírez, Luis Fein, Ruben D. Kowalyszyn, E. Douglas Kramer, Hui Wang, Min-Fun R. Kwan & David L. Cutler. (2023) Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer. Journal of Clinical Oncology 41:1, pages 65-74.
Crossref
Crossref
Deborah O. Onwusah, Elizabeth B. Ojewole & Moses J. Chimbari. (2023) Adherence to Oral Anticancer Medications Among Women With Breast Cancer in Africa: A Scoping Review. JCO Global Oncology:9.
Crossref
Crossref
Neil E. Fleshner, Shabbir M. H. Alibhai, Kim A. Connelly, Ilidio Martins, Bernhard J. Eigl, Himu Lukka & Armen Aprikian. (2023) Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review. Therapeutic Advances in Medical Oncology 15, pages 175883592311528.
Crossref
Crossref
Moataz M Hassan, Dhabya Al-Marzooq, Hanan Al-Habsi, Amna Al-Hashar, Murtadha Al-Khabori, Mansour Al-Moundhri & Ibrahim Al-Zakwani. (2021) Patients’ knowledge and awareness of safe handling of oral anticancer agents at Sultan Qaboos University Hospital in Oman. Journal of Oncology Pharmacy Practice 29:1, pages 112-118.
Crossref
Crossref
Pasquale Rescigno, Marco Maruzzo, Sara Elena Rebuzzi, Veronica Murianni, Marika Cinausero, Helga Lipari, Lucia Fratino, Teresa Gamba, Ugo De Giorgi, Orazio Caffo, Davide Bimbatti, Arianna Dri, Alessandra Mosca, Emilio Francesco Giunta, Paola Ermacora, Francesca Vignani, Aichi Msaki, Barbara Bonifacio, Valentina Lombardo, Vincenza Conteduca, Umberto Basso, Giuseppe Fornarini & Giuseppe Luigi Banna. (2022) Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network. The Oncologist 27:12, pages e949-e956.
Crossref
Crossref
M. Corvaisier, O. Duval, J. Paillassa, M. Hunault-Berger & L. Spiesser-Robelet. (2022) Mise en place de consultations pharmaceutiques en oncohématologie dans un centre hospitalo-universitaire : résultats à plus d’un an. Annales Pharmaceutiques Françaises.
Crossref
Crossref
Janice Patricia Richmond, Mary Grace Kelly, Patrick Jeremiah Murphy, Andrew William Murphy & Alison Johnston. (2022) Developing evidence-based standards for the administration of oral anti-cancer medicines. Cancer Nursing Practice.
Crossref
Crossref
Hitesh P. Gelli, Ruben Vazquez-Uribe & Morten Otto Alexander Sommer. (2022) Screening for effective cell-penetrating peptides with minimal impact on epithelial cells and gut commensals in vitro. Frontiers in Pharmacology 13.
Crossref
Crossref
Meng Li, Kaiping Liao, I-Wen Pan & Ya-Chen Tina Shih. (2022) Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer. JCO Oncology Practice 18:11, pages e1739-e1749.
Crossref
Crossref
F. Griesinger, G. Curigliano, M. Thomas, V. Subbiah, C.S. Baik, D.S.W. Tan, D.H. Lee, D. Misch, E. Garralda, D.-W. Kim, A.J. van der Wekken, J.F. Gainor, L. Paz-Ares, S.V. Liu, G.P. Kalemkerian, Y. Houvras, D.W. Bowles, A.S. Mansfield, J.J. Lin, V. Smoljanovic, A. Rahman, S. Kong, A. Zalutskaya, M. Louie-Gao, A.L. Boral & J. Mazières. (2022) Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial. Annals of Oncology 33:11, pages 1168-1178.
Crossref
Crossref
Xiomara Skrabal Ross, Kate M. Gunn, Vijayaprakash Suppiah, Pandora Patterson, Terry Boyle, Christine Carrington, Shir Ley Tan, Marissa Ryan, Rohit Joshi & Ian Olver. (2022) A smartphone program to support adherence to oral chemotherapy in people with cancer: Proof‐of‐concept trial. Asia-Pacific Journal of Clinical Oncology 18:5.
Crossref
Crossref
Justin C. Merritt, Stephen D. Richbart, Emily G. Moles, Ashley J. Cox, Kathleen C. Brown, Sarah L. Miles, Paul T. Finch, Joshua A. Hess, Maria T. Tirona, Monica A. Valentovic & Piyali Dasgupta. (2022) Anti-cancer activity of sustained release capsaicin formulations. Pharmacology & Therapeutics 238, pages 108177.
Crossref
Crossref
Abdallah Y. Naser, Richard Ofori-Asenso, Safaa Al Awawdeh, Sami Qadus, Hassan Alwafi & Danny Liew. (2022) Real World Adherence to and Persistence With Oral Oncolytics in Multiple Myeloma: A Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma and Leukemia 22:10, pages 760-773.
Crossref
Crossref
Alexander S Watson, Richard Gagnon, Eugene Batuyong, Nimira Alimohamed & Richard Lee-Ying. (2022) Real-World Cabazitaxel Use and Outcomes in Metastatic Castrate-Resistant Prostate Cancer: The Impact of Response to First ARPI. Clinical Genitourinary Cancer 20:5, pages 496.e1-496.e9.
Crossref
Crossref
Marco Di Nitto, Fabio Sollazzo, Valentina Biagioli, Gianluca Pucciarelli, Francesco Torino, Rosaria Alvaro & Ercole Vellone. (2022) Self-care behaviors in patients with cancer treated with oral anticancer agents: a systematic review. Supportive Care in Cancer 30:10, pages 8465-8483.
Crossref
Crossref
Yun Jiang, Madilyn Mason, Youmin Cho, Ankita Chittiprolu, Xingyu Zhang, Karen Harden, Yang Gong, Marcelline R. Harris & Debra L. Barton. (2022) Tolerance to oral anticancer agent treatment in older adults with cancer: a secondary analysis of data from electronic health records and a pilot study of patient-reported outcomes. BMC Cancer 22:1.
Crossref
Crossref
Se Ik Kim, Ji Hyun Kim, Joseph J. Noh, Seung-Ho Kim, Tae Eun Kim, Kidong Kim, Jeong-Yeol Park, Myong Cheol Lim, Jeong-Won Lee & Jae-Weon Kim. (2022) Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea. Gynecologic Oncology 166:3, pages 444-452.
Crossref
Crossref
Amer M. Zeidan, Jui-Hua Tsai, Milad Karimi, Jordana Schmier, Sayeli Jayade, Evangelos Zormpas, Audrey Hassan, Desiree Ruiters, Cindy Anthony, Kala Hill, Tim Wert & Marc Botteman. (2022) Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes. Clinical Lymphoma Myeloma and Leukemia 22:9, pages e853-e866.
Crossref
Crossref
Cassie Beisel, Tayla Poretta, Vanessa B. Sheppard, Alejandra Hurtado-de Mendoza, Heather Sipsma, Eleanore Fuqua, Brian Stwalley, Anthony Salvatore & Min Yang. (2022) Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior. Advances in Therapy 39:9, pages 4061-4075.
Crossref
Crossref
Eric P. Borrelli & Conor G. McGladrigan. (2021) Five Year Analysis Assessing the Trend in Prescribing and Expenditures of Oral Oncolytics for Medicare Part D: 2013-2017. Journal of Pharmacy Practice 35:4, pages 580-586.
Crossref
Crossref
Jessica E. Pritchard, Lauren E. Wilson, Samuel M. Miller, Melissa A. Greiner, Harvey Jay Cohen, Deborah R. Kaye, Tian Zhang & Michaela A. Dinan. (2022) Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma. Journal of the American Geriatrics Society 70:8, pages 2330-2343.
Crossref
Crossref
Esther E Freeman, Nicole C McCann, Aggrey Semeere, Krishna P Reddy, Miriam Laker-Oketta, Helen Byakwaga, Pamela P Pei, Maya E Hajny Fernandez, Samson Kiprono, Naftali Busakhala, Jeffery N Martin, Toby Maurer, Ingrid V Bassett, Kenneth A Freedberg & Emily P Hyle. (2022) Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis. The Lancet Global Health 10:8, pages e1179-e1188.
Crossref
Crossref
Subhashis Pal, Shivani Sharma, Konica Porwal, Mohammed Riyazuddin, Chirag Kulkarni, Sourav Chattopadhyay, Sabyasachi Sanyal, Jiaur R. Gayen & Naibedya Chattopadhyay. (2022) Oral Administration of Isovitexin, a Naturally Occurring Apigenin Derivative Showed Osteoanabolic Effect in Ovariectomized Mice: A Comparative Study with Teriparatide. Calcified Tissue International 111:2, pages 196-210.
Crossref
Crossref
Yu. A. Agafonova, D. V. Fedyaev, A. V. Snegovoy & V. V. Omelyanovskiy. (2022) Improving the efficiency of the medicine provision system for patients with malignant neoplasms. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15:2, pages 209-220.
Crossref
Crossref
Parveez Ahamed Abdul Azees, Suganthy Natarajan, Bennett T. Amaechi, Nooruddin Thajuddin, Vinay B. Raghavendra, Kathirvel Brindhadevi, Arivalagan Pugazhendhi & Tran Nhat Phuong. (2022) An empirical review on the risk factors, therapeutic strategies and materials at nanoscale for the treatment of oral malignancies. Process Biochemistry 118, pages 283-293.
Crossref
Crossref
Marco Di Nitto, Fabio Sollazzo, Valentina Biagioli, Francesco Torino, Rosaria Alvaro, Ercole Vellone & Angela Durante. (2022) Self-care behaviours in older adults treated with oral anticancer agents: A qualitative descriptive study. European Journal of Oncology Nursing 58, pages 102139.
Crossref
Crossref
Shintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, Kazuaki Harada, Takuto Miyagishima, Susumu Sogabe, Masayoshi Dazai, Atsushi Sato, Atsushi Ishiguro, Michio Nakamura, Shinya Kajiura, Yasuo Takahashi, Miki Tateyama, Kazuteru Hatanaka, Yasushi Tsuji, Takahide Sasaki, Yoshiaki Shindo, Tomoe Kobayashi, Isao Yokota, Naoya Sakamoto, Yuh Sakata & Yoshito Komatsu. (2022) Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. BMJ Open 12:5, pages e048833.
Crossref
Crossref
Laura A. Levit, Shaily Arora, Paul G. Kluetz, Allison Magnuson, Atiqur Rahman & R. Donald Harvey. (2022) Call to Action for Improving Oral Anticancer Agent Adherence. Journal of Clinical Oncology 40:10, pages 1036-1040.
Crossref
Crossref
Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet M. Manasanch, Jasper Olsem, Ashley Morphey, Xiao Jiao Huo, Sheeba K. Thomas, Qaiser Bashir, Muzaffar H. Qazilbash, Donna M. Weber & Robert Z. Orlowski. (2022) Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma. Clinical Cancer Research 28:7, pages 1277-1284.
Crossref
Crossref
Guillermo Garcia-Manero, Hartmut Döhner, Andrew H. Wei, Ignazia La Torre, Barry Skikne, CL Beach & Valeria Santini. (2022) Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies. Clinical Lymphoma Myeloma and Leukemia 22:4, pages 236-250.
Crossref
Crossref
Amer M. Zeidan, Sayeli Jayade, Jordana Schmier, Marc Botteman, Audrey Hassan, Desiree Ruiters, Kala Hill & Namita Joshi. (2022) Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients’ Perspectives on Treatment. Clinical Lymphoma Myeloma and Leukemia 22:3, pages e185-e198.
Crossref
Crossref
Brian L. Heiss, Daniel M. Geynisman, Elia Martinez, Alvin S. C. Wong, Wei Peng Yong, Russell Z. Szmulewitz & Walter M. Stadler. (2021) Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Supportive Care in Cancer 30:3, pages 2803-2810.
Crossref
Crossref
Alysia Cox, Siyoung A. Lim & Eun Ji Chung. (2022) Strategies to deliver RNA by nanoparticles for therapeutic potential. Molecular Aspects of Medicine 83, pages 100991.
Crossref
Crossref
Dominic Pilon, Joyce LaMori, Carmine Rossi, Mike Durkin, Isabelle Ghelerter, Xuehua Ke, Marie-Hélène Lafeuille, Lorie Ellis & Patrick Lefebvre. (2022) Medication adherence among patients with advanced prostate cancer using oral therapies. Future Oncology 18:2, pages 231-243.
Crossref
Crossref
Prajwal Dhakal, Christopher S Wichman, Bunny Pozehl, Meaghann Weaver, Alfred L Fisher, Julie Vose, R Gregory Bociek & Vijaya R Bhatt. (2022) Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?. Future Oncology 18:3, pages 311-321.
Crossref
Crossref
Amy Kang, Richard Beuttler & Emi Minejima. (2022) Evaluation of step-down oral antibiotic therapy for uncomplicated streptococcal bloodstream infections on clinical outcomes. Therapeutic Advances in Infectious Disease 9, pages 204993612110732.
Crossref
Crossref
Eric D. Eisenmann, Zahra Talebi, Alex Sparreboom & Sharyn D. Baker. (2021) Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactions. Basic & Clinical Pharmacology & Toxicology 130:S1, pages 23-35.
Crossref
Crossref
Emmanuelle Clou, Antonin Dubois, Julien Gaudas, Hugo Palisson, Kahina Chetouane, Chloé Talarmin, Olivia Meynial, Jacqueline Nguyen, Sandra Assoun, Marc-Antoine Benderra, Dhekra Nasrallah, Adoraction Esteso, Danièle Avenin, Gilles Galula, Djamel Ghebriou, Joseph Gligorov, Ahmed Khalil, Clément Korenbaum, Coralie Prebet, Hervé Foka-Tichoue, Jean-Pierre Lotz & Isabelle Debrix. (2022) A retrospective study of patients treated with by oral anticancer drugs: Impact of pharmacy consultation. European Journal of Oncology Pharmacy 5:4, pages e00033.
Crossref
Crossref
C. R. Arnold, A. K. Lindner, G. Schachtner, G. Tulchiner, N. Tulchiner, J. Mangesius, M. Maffei, W. Horninger, O. Kouvaiou, P. Lukas, U. Ganswindt, R. Pichler & S. Skvortsov. (2021) Vinorelbine in bladder-preserving multimodality treatment for muscle-invasive bladder cancer—a valid option for cisplatin-unfit patients?. Strahlentherapie und Onkologie 198:1, pages 25-32.
Crossref
Crossref
Amer M Zeidan, Tehseen Salimi & Robert S Epstein. (2021) Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. Future Oncology 17:36, pages 5163-5175.
Crossref
Crossref
Dylan J Hayes & John E Moore. (2020) Improving direct pharmacist counseling rates for oral oncolytic medications at an outpatient oncology clinic. Journal of Oncology Pharmacy Practice 27:8, pages 1861-1868.
Crossref
Crossref
Alison Brincat, Patricia Vella Bonanno, Derek Stewart & Anita E Weidmann. (2021) Patients’ experiences of medicines on initiation of antineoplastic agents for the treatment of colorectal cancer: a qualitative study. BMJ Open 11:12, pages e047749.
Crossref
Crossref
Sheba R. David, Khairunnasibah Abdullah, Rajeshkumar Shanmugam, Lakshmi Thangavelu, Sanjoy Kumar Das & Rajan Rajabalaya. (2021) Green Synthesis, Characterization and In Vivo Evaluation of White Tea Silver Nanoparticles with 5-Fluorouracil on Colorectal Cancer. BioNanoScience 11:4, pages 1095-1107.
Crossref
Crossref
Gwendoline Gautier, Mélodie Lucas, Thomas Vermeulin, Frederic Di Fiore & Veronique Merle. (2021) Deprived social status is associated with decreased use of oral chemotherapy in patients with metastatic colorectal cancer: A retrospective cohort study on administrative databases in a French University Hospital. Pharmacology Research & Perspectives 9:6.
Crossref
Crossref
Łukasz Banach, George T. Williams & John S. Fossey. (2021) Insulin Delivery Using Dynamic Covalent Boronic Acid/Ester‐Controlled Release. Advanced Therapeutics 4:11, pages 2100118.
Crossref
Crossref
Cian O'Mahony, Kevin D. Murphy & Stephen Byrne. (2021) A mixed methods analysis of the monitoring of oral anti-cancer therapies. European Journal of Oncology Nursing 54, pages 102026.
Crossref
Crossref
Marcos de Lima, Gail J. Roboz, Uwe Platzbecker, Charles Craddock & Gert Ossenkoppele. (2021) AML and the art of remission maintenance. Blood Reviews 49, pages 100829.
Crossref
Crossref
Baljinder Singh, Nutan Shukla, Junkee Kim, Kibeom Kim & Myoung-Hwan Park. (2021) Stimuli-Responsive Nanofibers Containing Gold Nanorods for On-Demand Drug Delivery Platforms. Pharmaceutics 13:8, pages 1319.
Crossref
Crossref
Mrinal Gounder, Albiruni R Abdul Razak, Adrienne M Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz Chmielowski, Robin L Jones, Jatin Shah, Sharon Shacham, Michael Kauffman, Richard F Riedel & Steven Attia. (2021) Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma. Future Oncology 17:22, pages 2923-2939.
Crossref
Crossref
Jelena Rosentreter, Jürgen Alt, Marius Fried, Geothy Chakupurakal, Jan Stratmann & Irene Krämer. (2020) Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors. Journal of Oncology Pharmacy Practice 27:5, pages 1147-1158.
Crossref
Crossref
Laura Cortesi, Hope S. Rugo & Christian Jackisch. (2021) An Overview of PARP Inhibitors for the Treatment of Breast Cancer. Targeted Oncology 16:3, pages 255-282.
Crossref
Crossref
Michael P. Smolinski, Sameer Urgaonkar, Laura Pitzonka, Murray Cutler, GwanSun Lee, Kwee Hyun Suh & Johnson Y. N. Lau. (2021) Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor. Journal of Medicinal Chemistry 64:7, pages 3677-3693.
Crossref
Crossref
Elisa Pierpaoli, Francesco Piacenza, Gaetano Fiorillo, Paolo Lombardi, Fiorenza Orlando, Carmela Salvatore, Cristina Geroni & Mauro Provinciali. (2021) Antimetastatic and Antitumor Activities of Orally Administered NAX014 Compound in a Murine Model of HER2-Positive Breast Cancer. International Journal of Molecular Sciences 22:5, pages 2653.
Crossref
Crossref
Rayan Sabra & Nashiru Billa. (2021) Soliciting the Oral Route as a Logical Approach to Managing Colon Cancer. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Crossref
Jacob William Coffey, Gaurav Das Gaiha & Giovanni Traverso. (2021) Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics. Annual Review of Pharmacology and Toxicology 61:1, pages 517-540.
Crossref
Crossref
Fred Saad & Neal D. Shore. (2021) Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology 13, pages 175883592199858.
Crossref
Crossref
Francesco Grossi, Piotr Jaśkiewicz, Marion Ferreira, Grzegorz Czyżewicz, Dariusz Kowalski, Libero Ciuffreda, Ramon Garcia-Gomez, Salvatore Caruso, Joaquim Bosch-Barrera, Stéphanie Gautier, Christine Ta Thanh Minh, Sébastien Henriet & Gilberto de CastroJr.Jr.. (2021) Oral vinorelbine and cisplatin as first-line therapy for advanced squamous NSCLC patients: a prospective randomized international phase II study (NAVoTrial 03). Therapeutic Advances in Medical Oncology 13, pages 175883592110229.
Crossref
Crossref
Hatim Karachiwala, Derek Tilley, Omar Abdel‐Rahman & Don Morris. (2020) Comparison of oral versus intravenous etoposide in the management of small‐cell lung cancer; A real‐world, population‐based study. The Clinical Respiratory Journal 15:1, pages 36-41.
Crossref
Crossref
Syeda Zunaira Bukhari, Kornelius Zeth, Maryam Iftikhar, Mubashar Rehman, Muhammad Usman Munir, Waheed S. Khan & Ayesha Ihsan. (2021) Supramolecular lipid nanoparticles as delivery carriers for non-invasive cancer theranostics. Current Research in Pharmacology and Drug Discovery 2, pages 100067.
Crossref
Crossref
Palma Fedele, Valeria Sanna, Alessandro Fancellu, Antonella Marino, Nicola Calvani & Saverio Cinieri. (2021) De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?. Critical Reviews in Oncology/Hematology 157, pages 103148.
Crossref
Crossref
Sanyog Jain, Kaisar Raza, Ashish Kumar Agrawal & Ankur Vaidya. 2021. Nanotechnology Applications for Cancer Chemotherapy. Nanotechnology Applications for Cancer Chemotherapy
589
597
.
Iqbal Ramzan & Reza Kahlaee. 2020. Biologics, Biosimilars, and Biobetters. Biologics, Biosimilars, and Biobetters
253
266
.
Juliette Périchou, Florence Ranchon, Chloé Herledan, Laure Huot, Virginie Larbre, Isabelle Carpentier, Anne Lazareth, Lionel Karlin, Karen Beny, Nicolas Vantard, Vérane Schwiertz, Anne Gaelle Caffin, Amandine Baudouin, Pierre Sesques, Gabriel Brisou, Hervé Ghesquières, Gilles Salles & Catherine Rioufol. (2020) Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects. PLOS ONE 15:12, pages e0243309.
Crossref
Crossref
Donna R RiveraLindsey EnewoldMichael J BarrettMatthew P BanegasKelly K FilipskiAndrew N FreedmanClara K LamAngela Mariotto. (2020) Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients. Journal of Managed Care & Specialty Pharmacy 26:12, pages 1494-1504.
Crossref
Crossref
Catherine H. Watson, Laura J. Fish, Margaret Falkovic, Karen Monuszko, Amelia Lorenzo, Laura J. Havrilesky, Angeles Alvarez Secord & Brittany A. Davidson. (2020) Adherence to Oral Anticancer Therapeutics in the Gynecologic Oncology Population. Obstetrics & Gynecology 136:6, pages 1145-1153.
Crossref
Crossref
Mei-Li Laracuente, Marina H. Yu & Kevin J. McHugh. (2020) Zero-order drug delivery: State of the art and future prospects. Journal of Controlled Release 327, pages 834-856.
Crossref
Crossref
Yunyue Zhang, Maya Thanou & Driton Vllasaliu. (2020) Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease. European Journal of Pharmaceutics and Biopharmaceutics 155, pages 128-138.
Crossref
Crossref
Robert M. Rifkin, Jill A. Bell, Pronabesh DasMahapatra, Michael Hoole, Maria Lowe, Chris Curran, Scott Campbell, Peijie Hou & Dorothy Romanus. (2019) Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma. PharmacoEconomics - Open 4:3, pages 473-483.
Crossref
Crossref
André O’Reilly Beringhs, Surya Pratap Singh, Tulio Alberto Valdez & Xiuling Lu. (2020) Sublingual indocyanine green films for non-invasive swallowing assessment and inflammation detection through NIR/SWIR optical imaging. Scientific Reports 10:1.
Crossref
Crossref
Stephanie J. Franks, Kate Firipis, Rita Ferreira, Katherine M. Hannan, Richard J. Williams, Ross D. Hannan & David R. Nisbet. (2020) Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents. Materials Horizons 7:8, pages 1996-2010.
Crossref
Crossref
Fatima Cardoso, Nils Wilking, Renato Bernardini, Laura Biganzoli, Jaime Espin, Kaisa Miikkulainen, Susanne Schuurman, Danielle Spence, Sabine Spitz, Sonia Ujupan, Nicole Zernik & Jenn Gordon. (2020) A multi-stakeholder approach in optimising patients’ needs in the benefit assessment process of new metastatic breast cancer treatments. The Breast 52, pages 78-87.
Crossref
Crossref
Shyamala C. Navada, Guillermo Garcia-Manero, Rosalie OdchimarReissig, Naveen Pemmaraju, Yesid Alvarado, Maro N. Ohanian, Rosmy B. John, Erin P. Demakos, Patrick S. Zbyszewski, Manoj Maniar, Richard C. Woodman, Steven M. Fruchtman & Lewis R. Silverman. (2020) Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. Leukemia Research 94, pages 106369.
Crossref
Crossref
Felipe Rodriguez, Sarah F. John, Eva Iniguez, Sebastian Montalvo, Karina Michael, Lyndsey White, Dong Liang, Omonike A. Olaleye & Rosa A. Maldonado. (2020)
In Vitro
and
In Vivo
Characterization of Potent Antileishmanial Methionine Aminopeptidase 1 Inhibitors
. Antimicrobial Agents and Chemotherapy 64:6.
Crossref
Crossref
Solange A. Valdes, Riyad F. Alzhrani, Dharmika S. P. Lansakara-P & Zhengrong Cui. (2020) Effect of a Solid Lipid Nanoparticle Formulation on the Bioavailability of 4-(N)-Docosahexaenoyl 2′, 2′-Difluorodeoxycytidine After Oral Administration. AAPS PharmSciTech 21:3.
Crossref
Crossref
Samantha H Spencer, Shannon M Menard, Malgorzata Z Labedz, Courtney D Krueger & Katherine V Sarna. (2020) Enteral tube administration of oral chemotherapy drugs. Journal of Oncology Pharmacy Practice 26:3, pages 703-717.
Crossref
Crossref
Xinyu Li, Yongwei Su, Katie Hege, Gerard Madlambayan, Holly Edwards, Tristan Knight, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Jay Yang, Regan Miller, Guan Wang, Lijing Zhao, Yue Wang, Hai Lin, Jeffrey W. Taub & Yubin Ge. (2020) The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia. Haematologica 106:5, pages 1262-1277.
Crossref
Crossref
Hani M. Babiker, Mohammed Milhem, Joseph Aisner, William Edenfield, Dale Shepard, Michael Savona, Swaminathan Iyer, Maen Abdelrahim, C. L. Beach, Barry Skikne, Eric Laille, Kao-Tai Tsai & Thai Ho. (2020) Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemotherapy and Pharmacology 85:3, pages 621-626.
Crossref
Crossref
Phuong Ha-Lien Tran, Tao Wang, Chunguang Yang, Thao T.D. Tran & Wei Duan. (2020) Development of conjugate-by-conjugate structured nanoparticles for oral delivery of docetaxel. Materials Science and Engineering: C 107, pages 110346.
Crossref
Crossref
Manuel Arruebo & Victor Sebastian. 2020. Nanotechnology for Oral Drug Delivery. Nanotechnology for Oral Drug Delivery
317
357
.
Ajai Chari, Dorothy Romanus, Pronabesh DasMahapatra, Michael Hoole, Maria Lowe, Chris Curran, Scott Campbell & Jill A. Bell. (2019) Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). The Oncologist 24:11, pages 1479-1487.
Crossref
Crossref
Eva María Ciruelos, María Nieves Díaz, María Dolores Isla, Rafael López, Reyes Bernabé, Encarnación González, Beatriz Cirauqui, Juan Coves, Serafín Morales, Alberto Arcediano, Isidoro Barneto, Pablo Cerezuela, José Juan Illarramendi, Cristina Morales & Santiago Ponce. (2019) Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. European Journal of Cancer Care 28:6.
Crossref
Crossref
Melanie Dalby, Shereen Nabhani-Gebara, Ranjita Dhital & Ian Norman. (2019) Feasibility of a referral pathway to community pharmacy for patients taking oral anticancer medication. Cancer Nursing Practice 18:5, pages 22-28.
Crossref
Crossref
Kellyn Moran, Kyle Null, Zhongwen Huang, Trevor Lissoos & Sunanda Kane. (2019) Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases. Advances in Therapy 36:9, pages 2260-2272.
Crossref
Crossref
Stephanie Y. Cheng, Farah E. Saxena, Soo Jin Seung, Craig C. Earle, Kelvin Chan & Nicole Mittmann. (2019) Demographic characteristics and cost of treatment among oncology patients in a publicly funded system, the Ontario Trillium Drug Program: a retrospective cohort study. CMAJ Open 7:3, pages E516-E523.
Crossref
Crossref
James R Miner, Timothy I Melson, David Leiman, Harold S Minkowitz, Yu-Kun Chiang, Karen P DiDonato & Pamela P Palmer. (2019) Pooled Phase III safety analysis of sufentanil sublingual tablets for short-term treatment of moderate-to-severe acute pain. Pain Management 9:3, pages 259-271.
Crossref
Crossref
M. Mauro, R.A. De Grandis, M.L. Campos, A. Bauermeister, R.G. Peccinini, F.R. Pavan, N.P. Lopes & N.V. De Moraes. (2019) Acid diterpenes from Copaiba oleoresin (Copaifera langsdorffii): Chemical and plasma stability and intestinal permeability using Caco-2 cells. Journal of Ethnopharmacology 235, pages 183-189.
Crossref
Crossref
Jamie M. JacobsMolly E. Ream, Nicole PensakLauren E. NisotelJoel N. FishbeinJames J. MacDonaldJoanne BuzagloInga T. LennesSteven A. Safren, William F. PirlJennifer S. TemelJoseph A. Greer. (2019) Patient Experiences With Oral Chemotherapy: Adherence, Symptoms, and Quality of Life. Journal of the National Comprehensive Cancer Network 17:3, pages 221-228.
Crossref
Crossref
Georgios K. Eleftheriadis, Panagiota Mantelou, Christina Karavasili, Paschalina Chatzopoulou, Dimitrios Katsantonis, Maria Irakli, Aggeliki Mygdalia, Ioannis S. Vizirianakis & Dimitrios G. Fatouros. (2019) Development and Characterization of a Self-Nanoemulsifying Drug Delivery System Comprised of Rice Bran Oil for Poorly Soluble Drugs. AAPS PharmSciTech 20:2.
Crossref
Crossref
Melissa Frizziero, Francesca Spada, Angela Lamarca, Zoe Kordatou, Jorge Barriuso, Christina Nuttall, Mairéad G. McNamara, Richard A. Hubner, Wasat Mansoor, Prakash Manoharan, Nicola Fazio & Juan W. Valle. (2019) Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. Neuroendocrinology 109:2, pages 100-112.
Crossref
Crossref
Philipp Lapuhs & Gregor Fuhrmann. 2019. Therapeutic Enzymes: Function and Clinical Implications. Therapeutic Enzymes: Function and Clinical Implications
151
172
.
Monica Hadi, Paul Swinburn, Luba Nalysnyk, Alaa Hamed & Atul Mehta. (2018) A health state utility valuation study to assess the impact of treatment mode of administration in Gaucher disease. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Jiexin Deng, Satjit S. Brar & Lawrence J. Lesko. (2018) To Take or Not to Take With Meals? Unraveling Issues Related to Food Effects Labeling for Oral Antineoplastic Drugs. Clinical Pharmacology in Drug Development 7:5, pages 455-464.
Crossref
Crossref
Abir Salwa Ali, Malin Grönberg, Seppo W. Langer, Morten Ladekarl, Geir Olav Hjortland, Lene Weber Vestermark, Pia Österlund, Staffan Welin, Henning Grønbæk, Ulrich Knigge, Halfdan Sorbye & Eva Tiensuu Janson. (2018) Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology 35:4.
Crossref
Crossref
Tsung Yu, Nomin Enkh-Amgalan & Ganchimeg Zorigt. (2017) Methods to perform systematic reviews of patient preferences: a literature survey. BMC Medical Research Methodology 17:1.
Crossref
Crossref
Carol MansfieldAnthony MasaquelJessie SutphinElisa Weiss, Meghan Gutierrez, Jennifer Wilson, Marco BoeriJia LiCarolina Reyes. (2017) Patients’ priorities in selecting chronic lymphocytic leukemia treatments. Blood Advances 1:24, pages 2176-2185.
Crossref
Crossref
Chun Gwon Park, Beom Kang Huh, Se-Na Kim, Seung Ho Lee, Hye Rim Hong & Young Bin Choy. (2017) Nanostructured mucoadhesive microparticles to enhance oral drug bioavailability. Journal of Industrial and Engineering Chemistry 54, pages 262-269.
Crossref
Crossref
Nitya Nathwani & Tanya M. Wildes. (2017) Study design for vulnerable older adults with multiple myeloma. Journal of Geriatric Oncology 8:3, pages 162-164.
Crossref
Crossref
Justin C. Merritt, Stephen D. Richbart, Emily G. Moles, Ashley J. Cox, Kathleen C. Brown, Sarah L. Miles, Paul T. Finch, Joshua C. Hess, Maria T. Tirona, Monica A. Valentovic & Piyali Dasgupta. (2021) Anti-Cancer Activity of Sustained Release Capsaicin Formulations. SSRN Electronic Journal.
Crossref
Crossref